<p>隨着年中臨近，Medtronic（紐約證券交易所代碼：MDT）的主要催化劑是，逆風對業績的影響並沒有預期的那麼嚴重。成本上升、利潤壓縮以及與宏觀經濟逆風相關的一般不確定性在公司 6 月 3 日的財報中有所體現，但業績本身強勁，預計將繼續保持強勁。</p>
<p>對股價的影響將是上漲，因為市場嚴重超賣，反彈的時機成熟。唯一的問題是股價可能上漲到多高，跡象表明 25% 的上漲空間是輕而易舉的。</p>
<p>Medtronic 的交易處於一個長期區間內，關鍵阻力位接近 95 美元。95 美元的水平比關鍵支撐位高出 25% 以上，而 MDT 股票在 6 月初的交易價格正處於該支撐位附近。雖然價格下跌仍然是一個可能性，但對 MDT 2026 財年第四季度財報的反應表明底部已經形成，反彈已經開始。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20260603130551_chart-mdt-632026-002.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20260603130551_chart-mdt-632026-002.png"/></p>
<h2>分析師和機構對 MDT 資本回報的信心</h2>
<p>分析師趨勢還表明 25% 的股價上漲是一個輕鬆的目標。在發佈前的趨勢混合，許多價格目標有所下調，但數據顯示他們只是修剪了目標，而不是進行大幅度的價格變動。最終結果是，儘管共識略有下降，但仍預測出強勁的 20% 上漲空間和創出新高的潛力。可能的結果是，第四季度的業績將重新激發市場對公司現金流生成能力的信心，這對這個故事至關重要。</p>
<p>Medtronic 是一家知名的分紅增長公司，正朝着成為分紅之王的目標邁進。第四季度的業績包括連續第 49 次分紅增加，約佔投資者的 1.4%，使其有望被納入更多指數並增強機構持股，這是股價的一個催化劑。目前，收益率約為 3.5%，而股票處於交易區間的低端，僅為盈利預期的 50%。可能的結果是，Medtronic 在業務和分紅方面都能持續增長，儘管增長速度可能永遠不會強勁。</p>
<p>機構對分紅和公司的內在價值表示信心，持有超過 80% 的股票。與指數相關的持股比例較高，但所有權基礎廣泛，且該羣體正在積累。MarketBeat 的數據揭示了連續六個季度的看漲行為，包括截至目前的 2026 年第二季度。從這個角度來看，可能的結果是，隨着機構利用價值與收益的組合，買入活動將繼續積累。以今年盈利預期的 13 倍交易，該股票相較於標準普爾 500 指數便宜，提供近四倍於標準普爾 500 指數跟蹤 ETF NYSEARCA: SPY 的收益率，並提供對物理人工智能和物聯網的低貝塔暴露。</p>
<h2>Medtronic 的投資組合表現出色</h2>
<p>Medtronic 在本季度表現良好，收入增長 9.9%，超過 98 億美元。收入比預期高出 200 個基點（bps），所有業務部門均表現強勁。心血管部門以 10.1% 的增長領先，心臟消融解決方案增長了 78%，而糖尿病護理增長了 8.1%，醫療外科增長了 5.1%，神經科學增長了 3%。</p>
<p>利潤率消息喜憂參半，但市場對最壞情況的擔憂顯而易見，這在發佈前的修正趨勢中得到了體現。調整後的稀釋每股收益下降了 4.3%，至 1.55 美元，但由於超出預期 65 個基點，且現金流和收益足以維持資產負債表的健康，整體影響得以抵消。</p>
<p>指引是另一個指向股價強勁上漲的因素。公司對 2027 財年的初步指引包括 7% 的有機收入增長和略快的收益增長。壞消息是這兩個目標略低於共識預測，但市場再次擔心更糟的情況。</p>
<p>今年的催化劑包括 MiniMed 的分拆。初步 IPO 已經完成，最後一步預計將在今年晚些時候完成。在此過程中，Medtronic 將允許現有股東將股票兑換為 MMED 股票，實際上是取消一項以換取另一項。最終結果將是分配剩餘的 80% MMED，並減少 MDT 股票。此舉還預計將推動更高的淨利潤，同時使更專注的公司能夠有效執行其戰略。</p>
<p>Medtronic 的風險保持不變。雖然傳統的召回和競爭風險在行業中無處不在，但它還面臨關税威脅和對網絡安全日益增長的需求。人工智能改變了網絡安全的遊戲，引入了數據中毒等新挑戰。不正確、不連貫和其他惡意數據對人工智能模型和影響健康結果的代理產生了毀滅性的影響。</p>
<h2>你現在應該投資 1000 美元在 Medtronic 嗎？</h2>
<p>在你考慮投資 Medtronic 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天向客户推薦的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場意識到之前……而 Medtronic 並不在名單上。</p>
<p>雖然 Medtronic 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

美敦力

MMED

<p>美敦力（MDT）在經歷過度拋售後，正準備反彈，分析師預計將有 20-25% 的上漲空間。強勁的第四季度業績顯示收入增長 9.9%，超出預期，同時公司保持了 3.5% 的股息收益率，繼續維持其 “股息之王” 的地位。機構信心依然強勁，即將進行的 MiniMed 分拆旨在提升利潤率。儘管面臨宏觀經濟逆風和網絡安全風險，美敦力以 13 倍的市盈率和強勁的現金流支撐了樂觀的前景</p>

<p>Medtronic's NYSE: MDT primary catalyst as mid-year approaches is that headwinds are not impairing results as much as feared. Rising costs, margin compression, and general uncertainty linked to macroeconomic headwinds were reflected in the company's June 3 earnings results, but the results were inherently strong and expected to remain so.</p>
<div class="lb-trans"><p>隨着年中臨近，Medtronic（紐約證券交易所代碼：MDT）的主要催化劑是，逆風對業績的影響並沒有預期的那麼嚴重。成本上升、利潤壓縮以及與宏觀經濟逆風相關的一般不確定性在公司 6 月 3 日的財報中有所體現，但業績本身強勁，預計將繼續保持強勁。</p>
</div><p>The impact on share prices will be a rise, as the market is deeply oversold and ripe for a rebound. The only question is how high the stock price might go, and the signs suggest a 25% upside is easy.</p>
<div class="lb-trans"><p>對股價的影響將是上漲，因為市場嚴重超賣，反彈的時機成熟。唯一的問題是股價可能上漲到多高，跡象表明 25% 的上漲空間是輕而易舉的。</p>
</div><p>Medtronic is trading within a long-term range, with critical resistance near $95. The $95 level is more than 25% above the critical support level, at which MDT stock trades as of early June. While lower prices remain a possibility, the response to MDT’s fiscal Q4 2026 earnings report suggests a bottom is in place, and the rebound has begun.</p>
<div class="lb-trans"><p>Medtronic 的交易處於一個長期區間內，關鍵阻力位接近 95 美元。95 美元的水平比關鍵支撐位高出 25% 以上，而 MDT 股票在 6 月初的交易價格正處於該支撐位附近。雖然價格下跌仍然是一個可能性，但對 MDT 2026 財年第四季度財報的反應表明底部已經形成，反彈已經開始。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20260603130551_chart-mdt-632026-002.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20260603130551_chart-mdt-632026-002.png"/></p>
<h2>Analysts and Institutions Reflect Confidence in MDT Capital Return</h2>
<div class="lb-trans"><h2>分析師和機構對 MDT 資本回報的信心</h2>
</div><p>Analyst trends also indicate that a 25% stock price increase is an easy target. Trends leading into the release were mixed, with numerous price target reductions, but the data reveal they simply trimmed targets, rather than making drastic price changes. The net result is that while consensus fell incrementally, it still forecasts a robust 20% upside and the potential for fresh highs. The likely outcome is that the Q4 results will trigger renewed confidence in the company’s ability to generate cash flow, which is significant to this story.</p>
<div class="lb-trans"><p>分析師趨勢還表明 25% 的股價上漲是一個輕鬆的目標。在發佈前的趨勢混合，許多價格目標有所下調，但數據顯示他們只是修剪了目標，而不是進行大幅度的價格變動。最終結果是，儘管共識略有下降，但仍預測出強勁的 20% 上漲空間和創出新高的潛力。可能的結果是，第四季度的業績將重新激發市場對公司現金流生成能力的信心，這對這個故事至關重要。</p>
</div><p>Medtronic is a known dividend grower on track to be crowned Dividend King. Q4 results included the 49th consecutive distribution increase, worth about 1.4% to investors, putting it on track for inclusion in more indexes and enhanced institutional ownership, a catalyst for share prices. As it stands, the yield is about 3.5%, with shares at the low end of the trading range and only 50% of the earnings outlook. The likely outcome is that Medtronic sustains growth over time, both in the business and in the dividend, although the pace may never be robust.</p>
<div class="lb-trans"><p>Medtronic 是一家知名的分紅增長公司，正朝着成為分紅之王的目標邁進。第四季度的業績包括連續第 49 次分紅增加，約佔投資者的 1.4%，使其有望被納入更多指數並增強機構持股，這是股價的一個催化劑。目前，收益率約為 3.5%，而股票處於交易區間的低端，僅為盈利預期的 50%。可能的結果是，Medtronic 在業務和分紅方面都能持續增長，儘管增長速度可能永遠不會強勁。</p>
</div><p>Institutions signal confidence in the dividend and the company’s intrinsic value, owning more than 80% of the stock. Index-related holdings are high, but the ownership base is broad, and the group is accumulating. MarketBeat data reveals six consecutive quarters of bullish behavior, including Q2 2026 so far. The likely outcome from this vector is that buying activity continues to accumulate as institutions take advantage of the value-to-yield combination. Trading at 13X this year’s earnings outlook, the stock is cheap compared to the S&amp;P 500, provides nearly four times the yield of the S&amp;P 500 Index Tracking ETF NYSEARCA: SPY, and provides low-beta exposure to physical AI and the Internet of Things.</p>
<div class="lb-trans"><p>機構對分紅和公司的內在價值表示信心，持有超過 80% 的股票。與指數相關的持股比例較高，但所有權基礎廣泛，且該羣體正在積累。MarketBeat 的數據揭示了連續六個季度的看漲行為，包括截至目前的 2026 年第二季度。從這個角度來看，可能的結果是，隨着機構利用價值與收益的組合，買入活動將繼續積累。以今年盈利預期的 13 倍交易，該股票相較於標準普爾 500 指數便宜，提供近四倍於標準普爾 500 指數跟蹤 ETF NYSEARCA: SPY 的收益率，並提供對物理人工智能和物聯網的低貝塔暴露。</p>
</div><h2>Medtronic’s Portfolio Stands Tall</h2>
<div class="lb-trans"><h2>Medtronic 的投資組合表現出色</h2>
</div><p>Medtronic had a good quarter with revenue rising by 9.9% to over $9.8 billion. The top line came in 200 basis points (bps) better than expected, underpinned by strength in all segments. Cardiovascular led with a 10.1% gain, driven by Cardiac Ablation Solutions' 78% increase, while diabetic care grew by 8.1%, medical-surgical by 5.1%, and neuroscience by 3%.</p>
<div class="lb-trans"><p>Medtronic 在本季度表現良好，收入增長 9.9%，超過 98 億美元。收入比預期高出 200 個基點（bps），所有業務部門均表現強勁。心血管部門以 10.1% 的增長領先，心臟消融解決方案增長了 78%，而糖尿病護理增長了 8.1%，醫療外科增長了 5.1%，神經科學增長了 3%。</p>
</div><p>Margin news was mixed, but the market feared the worst, as evidenced by the downtrend in revisions leading into the release. Adjusted diluted earnings declined 4.3% to $1.55, offset by a 65-basis-point outperformance and sufficient cash flow and earnings to sustain balance sheet health.</p>
<div class="lb-trans"><p>利潤率消息喜憂參半，但市場對最壞情況的擔憂顯而易見，這在發佈前的修正趨勢中得到了體現。調整後的稀釋每股收益下降了 4.3%，至 1.55 美元，但由於超出預期 65 個基點，且現金流和收益足以維持資產負債表的健康，整體影響得以抵消。</p>
</div><p>Guidance is another factor pointing to a robust increase in stock price. The company’s initial guidance for fiscal 2027 includes 7% organic revenue growth and slightly faster earnings growth. The bad news is that both targets were slightly below the consensus forecast, but, again, the market was fearing worse.</p>
<div class="lb-trans"><p>指引是另一個指向股價強勁上漲的因素。公司對 2027 財年的初步指引包括 7% 的有機收入增長和略快的收益增長。壞消息是這兩個目標略低於共識預測，但市場再次擔心更糟的情況。</p>
</div><p>This year’s catalysts include the MiniMedNASDAQ: MMED spin-off. The initial IPO has been completed, with the final step expected later this year. In it, Medtronic will enable existing shareholders to exchange shares for MMED shares, effectively canceling one in favor of the other. The net result will be the distribution of the remaining 80% of MMED and a reduction in MDT shares. The move is also expected to drive higher net margins while enabling more focused companies to execute their strategies effectively.</p>
<div class="lb-trans"><p>今年的催化劑包括 MiniMed 的分拆。初步 IPO 已經完成，最後一步預計將在今年晚些時候完成。在此過程中，Medtronic 將允許現有股東將股票兑換為 MMED 股票，實際上是取消一項以換取另一項。最終結果將是分配剩餘的 80% MMED，並減少 MDT 股票。此舉還預計將推動更高的淨利潤，同時使更專注的公司能夠有效執行其戰略。</p>
</div><p>Medtronic’s risks remain unchanged. While traditional recall and competition risk are omnipresent for the industry, it also faces tariff threats and a rising need for cybersecurity. AI changed the game in cybersecurity, introducing new challenges such as data poisoning. Incorrect, incoherent, and otherwise malicious data has a devastating impact on AI models and agentic-influenced health outcomes.</p>
<div class="lb-trans"><p>Medtronic 的風險保持不變。雖然傳統的召回和競爭風險在行業中無處不在，但它還面臨關税威脅和對網絡安全日益增長的需求。人工智能改變了網絡安全的遊戲，引入了數據中毒等新挑戰。不正確、不連貫和其他惡意數據對人工智能模型和影響健康結果的代理產生了毀滅性的影響。</p>
</div><h2>Should You Invest $1,000 in Medtronic Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Medtronic 嗎？</h2>
</div><p>Before you consider Medtronic, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Medtronic 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天向客户推薦的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場意識到之前……而 Medtronic 並不在名單上。</p>
</div><p>While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Medtronic 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

美敦力已觸底，預計將迎來健康反彈